These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

950 related items for PubMed ID: 18835761

  • 21. Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit.
    Pournaras S, Markogiannakis A, Ikonomidis A, Kondyli L, Bethimouti K, Maniatis AN, Legakis NJ, Tsakris A.
    J Antimicrob Chemother; 2006 Mar; 57(3):557-61. PubMed ID: 16431857
    [Abstract] [Full Text] [Related]

  • 22. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases.
    Santimaleeworagun W, Wongpoowarak P, Chayakul P, Pattharachayakul S, Tansakul P, Garey KW.
    Southeast Asian J Trop Med Public Health; 2011 Jul; 42(4):890-900. PubMed ID: 22299471
    [Abstract] [Full Text] [Related]

  • 23. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen.
    Shields RK, Kwak EJ, Potoski BA, Doi Y, Adams-Haduch JM, Silviera FP, Toyoda Y, Pilewski JM, Crespo M, Pasculle AW, Clancy CJ, Nguyen MH.
    Diagn Microbiol Infect Dis; 2011 Jun; 70(2):246-52. PubMed ID: 21353436
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii.
    Mutlu Yilmaz E, Sunbul M, Aksoy A, Yilmaz H, Guney AK, Guvenc T.
    Int J Antimicrob Agents; 2012 Oct; 40(4):332-6. PubMed ID: 22831842
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Antimicrobial resistance and existence of metallo-beta-lactamase in Acinetobacter species isolated from adult patients].
    Eser OK, Ergin A, Hasçelik G.
    Mikrobiyol Bul; 2009 Jul; 43(3):383-90. PubMed ID: 19795613
    [Abstract] [Full Text] [Related]

  • 29. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology.
    Poirel L, Nordmann P.
    Clin Microbiol Infect; 2006 Sep; 12(9):826-36. PubMed ID: 16882287
    [Abstract] [Full Text] [Related]

  • 30. Colistin efficacy in an experimental model of Acinetobacter baumannii endocarditis.
    Rodríguez-Hernández MJ, Jiménez-Mejias ME, Pichardo C, Cuberos L, García-Curiel A, Pachón J.
    Clin Microbiol Infect; 2004 Jun; 10(6):581-4. PubMed ID: 15191391
    [Abstract] [Full Text] [Related]

  • 31. In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates.
    Hong DJ, Kim JO, Lee H, Yoon EJ, Jeong SH, Yong D, Lee K.
    Diagn Microbiol Infect Dis; 2016 Oct; 86(2):184-9. PubMed ID: 27475960
    [Abstract] [Full Text] [Related]

  • 32. In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii.
    Dizbay M, Tozlu DK, Cirak MY, Isik Y, Ozdemir K, Arman D.
    J Antibiot (Tokyo); 2010 Feb; 63(2):51-3. PubMed ID: 19942947
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa.
    Aoki N, Tateda K, Kikuchi Y, Kimura S, Miyazaki C, Ishii Y, Tanabe Y, Gejyo F, Yamaguchi K.
    J Antimicrob Chemother; 2009 Mar; 63(3):534-42. PubMed ID: 19147523
    [Abstract] [Full Text] [Related]

  • 35. In vitro activities of tigecycline alone and in combination with colistin sulfate or sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii strains isolated from Intensive Care Units.
    Ozbek B, Otük G.
    Int J Antimicrob Agents; 2010 Aug; 36(2):191-2. PubMed ID: 20537868
    [No Abstract] [Full Text] [Related]

  • 36. In vitro Evaluation of the Colistin-Carbapenem Combination in Clinical Isolates of A. baumannii Using the Checkerboard, Etest, and Time-Kill Curve Techniques.
    Soudeiha MAH, Dahdouh EA, Azar E, Sarkis DK, Daoud Z.
    Front Cell Infect Microbiol; 2017 Aug; 7():209. PubMed ID: 28596943
    [Abstract] [Full Text] [Related]

  • 37. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU.
    Sheng WH, Wang JT, Li SY, Lin YC, Cheng A, Chen YC, Chang SC.
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):380-6. PubMed ID: 21558048
    [Abstract] [Full Text] [Related]

  • 38. In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates.
    Singkham-In U, Chatsuwan T.
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):169-174. PubMed ID: 29433997
    [Abstract] [Full Text] [Related]

  • 39. In vitro activity of rifampicin alone and in combination with imipenem against multidrug-resistant Acinetobacter baumannii harboring the blaOXA-72 resistance gene.
    Majewski P, Wieczorek P, Ojdana D, Sacha PT, Wieczorek A, Tryniszewska EA.
    Scand J Infect Dis; 2014 Apr; 46(4):260-4. PubMed ID: 24447252
    [Abstract] [Full Text] [Related]

  • 40. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains.
    Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C.
    Clin Infect Dis; 2007 Sep 01; 45(5):594-8. PubMed ID: 17682994
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 48.